文献速递前列腺癌男科与性医学

睾酮治疗不增加局限期前列腺癌根治后复发或死亡风险

Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-06-08

该研究基于美国退伍军人事务部国家数据库,纳入2001至2015年确诊的69,984例接受手术或放疗的局限期前列腺癌患者,分析治疗后接受睾酮治疗(TT)者的生化复发与死亡风险。中位随访6.95年,手术组469例(1.64%)、放疗组543例(1.31%)接受TT;与未使用者相比,两组生化复发、前列腺癌特异性死亡及全因死亡均无显著差异。结论提示,在合适患者中根治治疗后使用TT未增加复发或死亡风险。

要点

  • 根治术后接受TT者与未使用者相比,生化复发风险无显著差异。
  • 前列腺癌特异性死亡和全因死亡风险在TT组与对照组间无显著差异。
  • 数据提示,对合适的局限期前列腺癌根治后患者,TT可能是安全的。

核心结论

  • 在多种族国家队列中,局限期前列腺癌手术或放疗后接受TT未增加生化复发、前列腺癌特异性死亡或全因死亡风险。
  • 数据提示,对合适的局限期前列腺癌根治治疗后男性,TT是安全的。

研究设计与样本

  • 队列分析,使用美国退伍军人事务部国家信息与计算基础设施数据库。
  • 纳入2001至2015年确诊的69,984例局限期前列腺癌患者,均接受手术或放疗。
  • 手术患者28,651例,放疗患者41,333例;TT作为时间依赖协变量编码。
  • 生化复发定义:手术后PSA > 0.2 ng/mL;放疗后PSA > 最低点 + 2 ng/mL。
  • 采用累积发病率曲线、Fine-Gray竞争风险回归和Cox回归分析复发与死亡。

主要发现

  • 手术组469例(1.64%)和放疗组543例(1.31%)接受TT,中位随访6.95年。
  • 手术后TT使用者 vs 非使用者:生化复发HR 1.07;前列腺癌特异性死亡HR 0.72(p = 0.43);全因死亡HR 1.11(p = 0.43)。
  • 放疗后TT使用者 vs 非使用者:生化复发HR 1.07;前列腺癌特异性死亡HR 1.02(p = 0.95);全因死亡HR 1.02(p = 0.86)。

临床怎么用

  • 对于局限期前列腺癌根治性手术或放疗后的合适男性,可考虑使用TT而不必过度担忧增加复发或死亡风险。
  • 临床决策仍需结合患者个体情况,并注意本研究缺乏TT疗程和血清睾酮浓度详细数据。

局限性

  • 缺乏TT疗程和血清睾酮浓度的详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety of testosterone therapy (TT) after definitive treatment for localized prostate cancer remains undefined. We analyzed the risks of biochemical recurrence and mortality in men receiving TT after treatment for localized prostate cancer. METHODS: Cohort analysis using the national US Veterans Affairs Informatics and Computing Infrastructure. We identified 69,984 patients with localized prostate cancer diagnosed from 2001 to 2015 treated with surgery or radiation. We coded receipt of TT after treatment as a time-dependent covariate; used the National Death Index to identify cause of death; and defined biochemical recurrence as PSA > 0.2 ng/mL after surgery and nadir + 2 ng/mL after radiation. We analyzed recurrence and mortality using cumulative incidence curves, Fine-Gray competing risk regression, and Cox regression. RESULTS: This cohort included 28,651 surgery patients and 41,333 radiation patients, of whom 469 (1.64%) and 543 (1.31%), respectively, received TT with a median follow-up of 6.95 years. Comparing testosterone users to nonusers, there were no between-group differences in biochemical recurrence, prostate cancer-specific mortality, or overall mortality after surgery [hazard ratios (HR): 1.07; HR: 0.72 (p = 0.43); and HR: 1.11 (p = 0.43), respectively] or radiation [HR: 1.07; HR: 1.02 (p = 0.95); and HR: 1.02 (p = 0.86), respectively]. Limitations included lack of detailed data on TT duration and serum testosterone concentrations. CONCLUSIONS: In this multi-ethnic national cohort, TT did not increase the risks of biochemical recurrence or prostate cancer-specific or overall mortality after surgery or radiation. These data suggest that TT is safe in appropriate men after definitive treatment of localized prostate cancer.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Sarkar RR, Patel SH, Parsons JK, et al. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis. 2020. PMID: 32513967. doi:10.1038/s41391-020-0241-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。